Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up on Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $17.65, but opened at $18.51. Pulse Biosciences shares last traded at $19.25, with a volume of 35,220 shares.

Specifically, Director Robert W. Duggan bought 56,054 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were purchased at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the transaction, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Thursday, December 12th.

Pulse Biosciences Price Performance

The business has a fifty day moving average of $17.74 and a 200 day moving average of $16.50.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period last year, the business earned ($0.19) earnings per share.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its stake in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after acquiring an additional 69,696 shares during the period. Geode Capital Management LLC increased its position in shares of Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after purchasing an additional 97,565 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after acquiring an additional 9,639 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences in the 3rd quarter valued at approximately $588,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.